≡

Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2)

[Edit]

FMR1L2

Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2)
CCC K163
HGNC 4024
MGI 1346074
PubMed 11875043
RGD 1307011
UniProt P51116
Wiki FXR2
FXR2 is an RNA binding protein containing two KH domains and one RCG box, which is similar to FMRP and FXR1. It associates with polyribosomes, predominantly with 60S large ribosomal subunits. This encoded protein may self-associate or interact with FMRP and FXR1. It may have a role in the development of fragile X mental retardation syndrome. Sequence analysis predicted that the 673-amino acid protein, with high N-terminal homology to FMR1 and FXR1 and approximately 60% identity overall, contains 2 ribonucleoprotein K homology (KH) domains, which are involved in RNA binding. FXR2 is expressed as a 3.0-kb transcript in HeLa cells and in mouse brain. Immunoblot analysis showed that FXR2 is expressed as a 95-kD protein, although the predicted molecular weight was 74 kD.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Fragile X Mental Retardation Syndrome Related Protein 2 (FXR2) ELISA Kit Customized Service Offer
  1. "The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2."EMBO J. 14:5358-5366(1995) [PubMed] [Europe PMC] [Abstract]
  2. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  3. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  4. "The rat androgen-binding protein (ABP/SHBG) gene contains triplet repeats similar to unstable triplets: evidence that the ABP/SHBG and the fragile X-related 2 genes overlap."Steroids 63:2-4(1998) [PubMed] [Europe PMC] [Abstract]
  5. "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry."Anal. Chem. 76:2763-2772(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks."Cell 127:635-648(2006) [PubMed] [Europe PMC] [Abstract]
  7. "Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP."Hum. Mol. Genet. 17:3236-3246(2008) [PubMed] [Europe PMC] [Abstract]
  8. "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis."J. Proteome Res. 7:1346-1351(2008) [PubMed] [Europe PMC] [Abstract]
  9. "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
  10. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  11. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  12. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  13. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  14. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  15. "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation."Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract]
  16. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  17. "Structural studies of the tandem Tudor domains of fragile X mental retardation related proteins FXR1 and FXR2."PLoS ONE 5:E13559-E13559(2010) [PubMed] [Europe PMC] [Abstract]